Articles by Jill Wechsler - Pharmaceutical Executive

ADVERTISEMENT

Articles by Jill Wechsler

Costs and Coverage Challenge Medicare Drug Plans

Aug 1, 2013

Rate cuts and fraud concerns create problems for Part D plans and Part B providers.

Seeking Supply Chain Security

Jul 1, 2013

FDA wants pharma leaders to do more to ensure drug quality at home and abroad. Our Washington correspondent Jill Wechsler reports.

Washington Report: Innovation, Coverage, and Costs

Jun 1, 2013

The backlash against high prices for new medicines will impact research, patent exclusivity, and drug benefits.

Manufacturers Under Pressure to Manage Painkillers

Opioid abuse generates calls for efforts to curb distribution, develop abuse-resistant formulations.
May 6, 2013

Opioid abuse generates calls for efforts to curb distribution, develop abuse-resistant formulations.

Generic Drug Gains and Grumbles

May 1, 2013

Legal battles and regulatory missteps undermine access to low-cost generics, at home and abroad, writes Jill Wechsler.

Full Disclosure for Pharma

Apr 1, 2013

There seems no end to demands for data on clinical research, conflicts of interest, company payments, and drug prices.

Another Round of FDA Legislation?

Mar 1, 2013

Pressure for action on key enforcement and regulatory issues may prompt congressional action this year.

Breakthrough Year for New Drugs

Feb 1, 2013

More new medicines gained market approval in 2012, but marketers face resistance from payers looking to cut healthcare spending, writes Jill Wechsler.

Transformation to Characterize 2013

Jan 1, 2013

FDA policies will reshape drug development, while pressure to cut healthcare spending may alter drug coverage and pricing.

ADVERTISEMENT

Click here